Antiviral medications in seasonal and pandemic influenza-A systematic review;Originalarbeit: Antivirale Arzneimittel bei saisonaler und pandemischer Influenza: Ein systematisches Review

Deutsches Arzteblatt International

Volumn 113, Issue 47, 2016, Pages 799-807

  Lehnert, Regine ^a   Pletz, Mathias ^b   Reuss, Annicka ^c   Schaberg, Tom ^d  

^a Bundesinstitut fur Arzneimittel und Medizinproducte   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d Agaplesion Diakoniekrankenhaus Rotenburg Wümme   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; SIALIDASE;

ANTIVIRAL THERAPY; ARTICLE; HUMAN; INFLUENZA A; PANDEMIC INFLUENZA; SEASONAL INFLUENZA; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; GERMANY; INFLUENZA; PANDEMIC; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEASON;

ANTIVIRAL AGENTS; GERMANY; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; PANDEMICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEASONS;

EID: 85000384382     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. European Medicines Agency: Updated review of influenza antiviral medicinal products for potential use during pandemic by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA). www.ema.europa.eu/docs/en-GB/document-library/Report/2009/11/WC500011117.pdf (last accessed on 20 September 2016).
2. World Health Organization: WHO Guidelines for Pharmacological Management of Pandemic Influenza A (H1N1) 2009 and other influenza viruses. www.who.int/csr/resources/publications/swineflu/h1n1-guidelines-pharmaceutical-mngt.pdf (last accessed on 20 September 2016).
3. Robert Koch-Institut: Nationaler Pandemieplan. www.rki.de/DE/Con tent/InfAZ/I/Influenza/Pandemieplanung/Nationaler-Influenzapan demieplan.html (last accessed on 20 September 2016).
4. Meyer R: Tamiflu: Eine unendliche Geschichte um Datentransparenz. Dtsch Arztebl 2013;110:A-132.
5. Meyer R: Neue Meta-Analyse stellt Wirkung infrage. Dtsch Arztebl. www.aerzteblatt.de/nachrichten/58300 (last accessed on 20 September 2016).
6. World Health Organization: WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. www.who.int/csr/resources/publications/swineflu/h1n1-use-antivirals-20090820/en/(last accessed on 20 September 2016).
7. European Centers for Disease Control: Draft scientific advice for consulation. ECDC preliminary scientific advice. Expert opinion on neuraminidase inhibitors for prevention and treatment of influenza. Review of recent systematic reviews and meta-analyses. http://ecdc.europa.eu/en/publications/publications/neuraminidaseinhibitors-flu-consultation.pdf (last accessed on 20 September 2016).
8. Centers for Disease Control: Antiviral drugs-information for health care professionals. www.cdc.gov/flu/professionals/antivirals/index.htm (last accessed on 20 September 2016).
9. Public Health England: Guidance. Influenza: treatment and prophy - laxis using anti-viral agents./www.gov. uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents (last accessed on 20 September 2016).
10. Ewig S, Höffken G, Kern WV, et al.: Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention - Update 2016. Pneumologie 2016;70:151-200.
11. Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S: The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PloS One 2013;8:e60348.
12. Tappenden P, Jackson R, Cooper K, et al.: Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess 2009;13:iii, ix-xii, 1-246.
13. Jackson RJ, Cooper KL, Tappenden P, et al.: Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect 2011;62:14-25.
14. Khazeni N, Bravata D M, Holty JE, Uye Ki TM, Stave CD, Gould MK: Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med 2009;151:464-73.
15. Jefferson T, Jones MA, Doshi P, et al.: Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014;4:CD008965.
16. Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D: Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev 2006; (2): CD001169.
17. Alves Galvao MG, Rocha Crispino Santos MA, Alves Da Cunha AJ: Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database Syst Rev 2014;11:CD002745.
18. Wang K, Shun-Shin M, Gill P, Perera R, Harnden A: Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev 2012;4:CD002744.
19. Ison MG, Szakaly P, Shapira M Y, Krivan G, Nist A, Dutkowski R: Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients. Antivir Ther 2012;17:955-64.
20. Monto AS, Pichichero ME, Blanckenberg SJ, et al.: Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002;186:1582-8.
21. Burch J, Paulden M, Conti S, et al.: Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess 2009;13:1-265, iii-iv.
22. Dobson J, Whitley RJ, Pocock S, Monto AS: Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015;385:1729-37.
23. Muthuri SG, Venkatesan S, Myles PR, et al.: Effectiveness of neu raminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a metaanalysis of individual participant data. Lancet Respir Med 2014;2:395-404.
24. Freemantle N, Shallcross LJ, Kyte D, Rader T, Calvert MJ: Oseltamivir: the real world data. BMJ 2014;348:g2371.
25. Jefferson T, Jones MA, Doshi P, et al.: Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012;1:CD008965.
26. Lipsitch M, Hernan MA: Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011;53:277-9.
27. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS: Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A (H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013;207:553-63.
28. Muthuri SG, Venkatesan S, Myles PR, et al.: Impact of neuramini - dase inhibitors on influenza A (H1N1) pdm09-related pneumonia: an individual participant data meta-analysis. Influenza Other Respir Viruses 2016:192-204.
29. Fry AM, Goswami D, Nahar K, et al.: Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis 2014;14:109-18.
30. Jefferson T, Jones M, Doshi P, Del Mar. C, Dooley L, Foxlee R: Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2010:CD001265.
31. Nicholson KG, Aoki F Y, Osterhaus AD, et al.: Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355:1845-50.
32. Aoki F Y, Macleod MD, Paggiaro P, et al.: Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003;51:123-9.
33. Adisasmito W, Chan PK, Lee N, et al.: Effectiveness of antiviral treatment in human influenza A (H5N1) infections: analysis of a global patient registry. J Infect Dis 2010;202:1154-60.
34. Bautista E, Chotpitayasunondh T, Gao Z, et al.: Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010;362:1708-19.
35. Anekthananon T, Pukrittayakamee S, Ratanasuwan W, et al.: Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks. J Antimicrob Chemother 2013;68:697-707.
36. European Medicines Agency: Tamiflu product information. www.ema. europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000402/human-med-001075.jsp&mid=WC0b01ac058001d124 (last accessed on 20 September 2016).
37. Läkemedelsverket, Medical Products Agency: Relenza product information. https://lakemedelsverket.se/LMF/Lakemedelsinformation/?nplid=19990209000018&type=product (last accessed on 20 September 2016).
38. Pharmnet. Bund: Fachinformation Relenza. www.pharmnet-bund.de/dynamic/de/arzneimittel-informationssystem/index.html (last access ed on 20 September 2016).
39. Meijer A, Lackenby A, Hungnes O, et al.: Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009;15:552-60.
40. Jagannath VA, Asokan GV, Fedorowicz Z, Lee TW: Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Cochrane Database Syst Rev 2014;2:CD008139.